Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pfizer Inc.

Product Revenues

Product Revenues %Chg

Product Revenues Common Size

Alliance Revenues

Alliance Revenues %Chg

Alliance Revenues Common Size

Royalty Revenues

Royalty Revenues %Chg

Royalty Revenues Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Selling, Informational and Administrative Expenses

Selling, Informational and Administrative Expenses %Chg

Selling, Informational and Administrative Expenses Common Size

Research and Development Expenses

Research and Development Expenses %Chg

Research and Development Expenses Common Size

Acquired in-Process Research and Development Expenses

Acquired in-Process Research and Development Expenses %Chg

Acquired in-Process Research and Development Expenses Common Size

Amortization of Intangible Assets

Amortization of Intangible Assets %Chg

Amortization of Intangible Assets Common Size

Restructuring Charges and Certain Acquisition-Related Costs

Restructuring Charges and Certain Acquisition-Related Costs %Chg

Restructuring Charges and Certain Acquisition-Related Costs Common Size

Reduction of Costs on Completion of Consumer Healthcare JV Transaction

Reduction of Costs on Completion of Consumer Healthcare JV Transaction %Chg

Reduction of Costs on Completion of Consumer Healthcare JV Transaction Common Size

Other Income-Net

Other Income-Net %Chg

Other Income-Net Common Size

Income from Continuing Operations Before Provision for Taxes on Income

Income from Continuing Operations Before Provision for Taxes on Income %Chg

Income from Continuing Operations Before Provision for Taxes on Income Common Size

Provision for Taxes on Income

Provision for Taxes on Income %Chg

Provision for Taxes on Income Common Size

Income from Continuing Operations

Income from Continuing Operations %Chg

Income from Continuing Operations Common Size

Income from Discontinued Operations-Net of Tax

Income from Discontinued Operations-Net of Tax %Chg

Income from Discontinued Operations-Net of Tax Common Size

Gain on Disposal of Discontinued Operations-Net of Tax

Gain on Disposal of Discontinued Operations-Net of Tax %Chg

Gain on Disposal of Discontinued Operations-Net of Tax Common Size

Discontinued Operations-Net of Tax

Discontinued Operations-Net of Tax %Chg

Discontinued Operations-Net of Tax Common Size

Net Income Before Allocation to Noncontrolling Interests

Net Income Before Allocation to Noncontrolling Interests %Chg

Net Income Before Allocation to Noncontrolling Interests Common Size

Less: Net Income Attributable to Noncontrolling Interests

Less: Net Income Attributable to Noncontrolling Interests %Chg

Less: Net Income Attributable to Noncontrolling Interests Common Size

Net Income Attributable to Pfizer Inc. Common Shareholders

Net Income Attributable to Pfizer Inc. Common Shareholders %Chg

Net Income Attributable to Pfizer Inc. Common Shareholders Common Size

Income from Continuing Operations Attributable to Pfizer Inc. Common Shareholders

Income from Continuing Operations Attributable to Pfizer Inc. Common Shareholders %Chg

Income from Continuing Operations Attributable to Pfizer Inc. Common Shareholders Common Size

Weighted-Average Shares-Basic

Weighted-Average Shares-Basic %Chg

Weighted-Average Shares-Basic Common Size

Weighted-Average Shares-Diluted

Weighted-Average Shares-Diluted %Chg

Weighted-Average Shares-Diluted Common Size

Cash Dividends Paid per Common Share

Cash Dividends Paid per Common Share %Chg

Cash Dividends Paid per Common Share Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Depreciation & Amortization Expenses

Depreciation & Amortization Expenses %Chg

Depreciation & Amortization Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Other Operating Expenses

Other Operating Expenses %Chg

Other Operating Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Consolidated Net Income

Consolidated Net Income %Chg

Consolidated Net Income Common Size

Net Income Attributable to Minority Interests and Other

Net Income Attributable to Minority Interests and Other %Chg

Net Income Attributable to Minority Interests and Other Common Size

Net Income Attributable to Discontinued Operations

Net Income Attributable to Discontinued Operations %Chg

Net Income Attributable to Discontinued Operations Common Size

Net Income Attributable to Common Shareholders

Net Income Attributable to Common Shareholders %Chg

Net Income Attributable to Common Shareholders Common Size

Basic EPS

Basic EPS %Chg

Basic EPS Common Size

Diluted EPS

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	LTM	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
Total Revenues	62,785	63,627	59,553	101,175	81,288	41,651	40,905	40,825	52,546	52,824	48,851
Total Revenues %Chg	3.9%	6.8%	-41.1%	24.5%	95.2%	1.8%	0.2%	-22.3%	-0.5%	8.1%	-1.5%
Product Revenues
Alliance Revenues
Royalty Revenues
Cost of Sales	16,704	17,851	24,954	34,344	30,821	8,484	8,054	8,987	11,228	12,322	9,648
Cost of Sales
Gross Profit	46,081	45,776	34,599	66,831	50,467	33,167	32,851	31,838	41,318	40,502	39,203
Gross Profit Margin	73.4%	71.9%	58.1%	66.1%	62.1%	79.6%	80.3%	78%	78.6%	76.7%	80.3%
Selling, General & Administrative Expenses	13,906	14,730	14,771	13,677	12,703	11,597	12,726	12,612	14,804	14,844	14,809
Selling, Informational and Administrative Expenses
Depreciation & Amortization Expenses	5,004	5,286	4,733	3,609	3,700	3,348	4,429	4,736	4,758	4,056	3,728
Amortization of Intangible Assets
Research & Development Expenses	11,755	10,930	10,873	12,381	13,829	9,393	8,385	7,760	7,683	7,892	7,690
Research and Development Expenses
Acquired in-Process Research and Development Expenses
Other Operating Expenses	6,263	6,807	3,165	2,437	-4,076	1,792	-4,009	3,135	1,767	5,359	4,012
Restructuring Charges and Certain Acquisition-Related Costs
Reduction of Costs on Completion of Consumer Healthcare JV Transaction
Other Income-Net
Operating Profit	9,153	8,023	1,057	34,727	24,311	7,037	11,320	3,595	12,306	8,351	8,964
Operating Margin	14.6%	12.6%	1.8%	34.3%	29.9%	16.9%	27.7%	8.8%	23.4%	15.8%	18.3%
Income Before Provision for Income Taxes	9,153	8,023	1,057	34,727	24,311	7,037	11,320	3,595	12,306	8,351	8,964
Provision for Income Taxes	-685	-28	-1,115	3,328	1,852	370	583	-266	-9,049	1,123	1,990
Provision for Taxes on Income
Consolidated Net Income	9,838	8,051	2,172	31,399	22,459	6,667	10,737	3,861	21,355	7,228	6,974
Net Income Attributable to Minority Interests and Other	41	31	39	35	45	36	29	36	47	31	26
Less: Net Income Attributable to Noncontrolling Interests
Net Income Attributable to Discontinued Operations	—	—	—	—	—	—	—	—	2	16	11
Income from Discontinued Operations-Net of Tax
Gain on Disposal of Discontinued Operations-Net of Tax
Net Income Attributable to Common Shareholders	9,828	8,031	2,119	31,372	21,979	9,159	16,026	11,153	21,308	7,215	6,960
Net Income Attributable to Pfizer Inc. Common Shareholders
Basic EPS	1.7	1.4	0.4	5.6	3.9	1.2	2.9	1.9	3.6	1.2	1.1
Diluted EPS	1.7	1.4	0.4	5.5	3.9	1.2	2.8	1.9	3.5	1.2	1.1
Basic Weighted Average Shares Outstanding	5,678	5,664	5,643	5,608	5,601	5,555	5,569	5,872	5,970	6,089	6,176
Total Shares Outstanding	5,685.7	5,667	5,646	5,616	5,620	5,567	5,534	5,717	5,979	6,070	6,175
Diluted Weighted Average Shares Outstanding	5,708.3	5,700	5,709	5,733	5,708	5,632	5,675	5,977	6,058	6,159	6,257
EBITDA	15,849	15,036	7,347	39,791	29,502	11,718	17,075	9,745	18,575	14,108	14,121
Effective Tax Rate	-7.5%	-0.3%	-105.5%	9.6%	7.6%	5.3%	5.2%	-7.4%	-73.5%	13.4%	22.2%